Additional Results from Phase I Study Show Inovio's INO-5150 Stabilizing Effect on Prostate Cancer

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced on 5/18/18 a poster presentation of additional prostate cancer data (Abstract #229675) at the American Society of Clinical Oncology (ASCO) annual meeting to be held in Chicago, June 1-5, 2018. Previously reported data from a Phase 1b clinical trial demonstrated that Inovio’s cancer immunotherapy (INO-5150) slowed PSA rise in patients with biochemically recurrent prostate cancer.